Biohaven Research Ltd

BHVN

Equity

ISIN VGG1110E1079 / Valor 121902526

New York Stock Exchange, Inc (2026-03-27)

USD 8.37-6.17%

Biohaven Research Ltd
UMushroom community rating:

3.90 10 votes No rating yet

NegativeNeutralPositive

About company

Biohaven Research Ltd is a biopharmaceutical company that has demonstrated a strong track record in developing and commercializing innovative therapies, particularly in the field of neurology. The company gained significant attention for its development of Nurtec® ODT (rimegepant), a groundbreaking treatment for migraine, which acts as both a preventive and acute therapy for migraine attacks. This novel CGRP receptor antagonist received approval from the FDA and the European Medicines Agency (EMA), marking a significant milestone in migraine treatment. Prior to its acquisition by Pfizer in May 2022, Biohaven's CGRP platform, including Nurtec ODT, achieved notable success, with Nurtec ODT becoming the leading prescribed medication in its class within two years of its launch in 2020. This achievement underscores Biohaven's capability in not only developing but also effectively commercializing treatments that address critical needs in the healthcare sector, particularly in areas with significant patient demand.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-70.5%1Y

-40.5%3Y

%5Y

Performance

101%1Y

79.3%3Y

84.3%5Y

Volatility